dc.contributor.author |
McLay, James S |
en |
dc.contributor.author |
Engelhardt, Thomas |
en |
dc.contributor.author |
Mohammed, Baba S |
en |
dc.contributor.author |
Cameron, Gary |
en |
dc.contributor.author |
Cohen, Mindy N |
en |
dc.contributor.author |
Galinkin, Jeffrey L |
en |
dc.contributor.author |
Christians, Uwe |
en |
dc.contributor.author |
Avram, Michael J |
en |
dc.contributor.author |
Henthorn, Thomas K |
en |
dc.contributor.author |
Dsida, Richard M |
en |
dc.contributor.author |
Hawwa, Ahmed F |
en |
dc.contributor.author |
Anderson, Brian |
en |
dc.date.accessioned |
2018-11-26T01:04:49Z |
en |
dc.date.issued |
2018-02 |
en |
dc.identifier.issn |
1155-5645 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/44582 |
en |
dc.description.abstract |
BACKGROUND:Intravenous ketorolac is commonly administered to children for the control of postoperative pain. An effect site EC50 for analgesia of 0.37 mg. L-1 is described in adults. AIMS:The aim of this study was to review age- and weight-related effects on ketorolac pharmacokinetic parameters in children and current dosing schedules. METHODS:Pooled intravenous ketorolac (0.5 mg. kg-1 ) concentration-time data in children aged 2 months to 16 years were analyzed using nonlinear mixed-effects models. Allometry was used to scale to a 70 kg person. RESULTS:There were 64 children aged 2 months to 16 years (641 plasma concentrations) available for analysis. A two-compartment mammillary model was used to describe pharmacokinetics. Clearance was 2.53 (CV 45.9%) L. h-1. 70 kg-1 and intercompartment clearance was 4.43 (CV 95.6%) L. h-1. 70 kg-1 . Both central (V1) and peripheral (V2) volumes of distribution decreased with age over the first few years of postnatal life to reach V1 6.89 (CV 30.3%) L. 70 kg-1 and V2 5.53 (CV 47.6%) L. 70 kg-1 . CONCLUSION:Clearance, expressed as L. h-1. kg-1 , decreased with age from infancy. A dosing regimen of 0.5 mg. kg-1 every 6 hours maintains a trough concentration larger than 0.37 mg. L-1 in children 9 months to 16 years of age. This dosing regimen is consistent with current recommendations. |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
Paediatric anaesthesia |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Humans |
en |
dc.subject |
Pain, Postoperative |
en |
dc.subject |
Ketorolac |
en |
dc.subject |
Anti-Inflammatory Agents, Non-Steroidal |
en |
dc.subject |
Age Factors |
en |
dc.subject |
Adolescent |
en |
dc.subject |
Child |
en |
dc.subject |
Child, Preschool |
en |
dc.subject |
Infant |
en |
dc.subject |
Female |
en |
dc.subject |
Male |
en |
dc.subject |
Administration, Intravenous |
en |
dc.title |
The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1111/pan.13302 |
en |
pubs.issue |
2 |
en |
pubs.begin-page |
80 |
en |
pubs.volume |
28 |
en |
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
29266539 |
en |
pubs.end-page |
86 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
719553 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Anaesthesiology |
en |
dc.identifier.eissn |
1460-9592 |
en |
pubs.record-created-at-source-date |
2017-12-22 |
en |
pubs.dimensions-id |
29266539 |
en |